Cosmos Health Inc (COSM) Stock AnalysisCOSMStock AnalysisCosmos Health Inc

Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cosmos Health Inc is a good buy right now due to its recent entry into the Saudi market with a significant distribution deal expected to generate stable revenue, alongside a notable 28% revenue growth reported in Q2 2026. The current price of $0.2247 is well below its 200-day simple moving average of $0.364, indicating potential for recovery. However, the company reported a net loss of $6.09 million in Q2 2026, which remains a risk to consider.